4.8 Article

Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system

Journal

NATURE COMMUNICATIONS
Volume 7, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms10934

Keywords

-

Funding

  1. AIRC MFAG
  2. Bando Giovani Ricercatori [2009-GR 1603126]
  3. FP7 ERC-StG [242965]
  4. Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-12023]
  5. Koch Institute/DFCC Bridge Project Fund
  6. Ellison Foundation Boston
  7. Worldwide Cancer Research [12-0216, R01 CA196703-01]
  8. European Research Council (ERC) [242965] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

Applications of the CRISPR-Cas9 system to edit the genome have widely expanded to include DNA gene knock-out, deletions, chromosomal rearrangements, RNA editing and genome-wide screenings. Here we show the application of CRISPR-Cas9 technology to edit the mouse and human immunoglobulin (Ig) genes. By delivering Cas9 and guide-RNA (gRNA) with retro- or lenti-virus to IgM(+) mouse B cells and hybridomas, we induce class-switch recombination (CSR) of the IgH chain to the desired subclass. Similarly, we induce CSR in all human B cell lines tested with high efficiency to targeted IgH subclass. Finally, we engineer mouse hybridomas to secrete Fab' fragments instead of the whole Ig. Our results indicate that Ig genes in mouse and human cells can be edited to obtain any desired IgH switching helpful to study the biology of normal and lymphoma B cells. We also propose applications that could transform the technology of antibody production.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available